0001437749-22-011133 8-K 15 20220505 2.02 9.01 20220505 20220505 SAFEGUARD SCIENTIFICS INC 0000086115 6799 231609753 PA 1231 8-K 34 001-05620 22896531 150 NORTH RADNOR-CHESTER ROAD SUITE F-200 RADNOR PA 19087 610 293 0600 150 NORTH RADNOR-CHESTER ROAD SUITE F-200 RADNOR PA 19087 SAFEGUARD INDUSTRIES INC 19810525 SAFEGUARD CORP 19690521 8-K 1 sfe20220504_8k.htm FORM 8-K sfe20220504_8k.htm
false 0000086115 0000086115 2022-05-05 2022-05-05
 


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 5, 2022
 
Safeguard Scientifics, Inc.
(Exact Name of registrant as Specified in Charter)
 
 
Pennsylvania
1-5620
23-1609753
(State or other Jurisdiction of
Incorporation)
(Commission File Number)
(IRS Employer ID No.)
 
150 N. Radnor Chester Rd., STE F-200
Radnor, PA
19087
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant’s telephone number, including area code: 610-293-0600
 
Not applicable 

(Former Name or Former Address if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock ($.10 par value)
SFE
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

 
Item 2.02.
Results of Operations and Financial Condition.
 
On May 5, 2022 Safeguard Scientifics, Inc. (the “Company”) issued a press release setting forth the Company’s financial information for the first quarter ended March 31, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.
 
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
ITEM 9.01.
Financial Statements and Exhibits.
 
(d)
Exhibits.
 
99.1
104
Cover Page Interactive Data File (formatted as Inline XBRL).
 
2

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Safeguard Scientifics, Inc.
     
     
Date: May 5, 2022
By:
/s/ G. Matthew Barnard
 
Name:      G. Matthew Barnard
 
Title:        General Counsel
   
 
3
EX-99.1 2 ex_370903.htm EXHIBIT 99.1 ex_370903.htm

Exhibit 99.1

safeguard01.jpg

SAFEGUARD SCIENTIFICS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

 

 

Conference call and webcast on May 5, 2022 at 5 p.m. ET

 

 

Radnor, PA, May 5, 2022Safeguard Scientifics, Inc. (NYSE:SFE) (“Safeguard” or the “Company”) today announced financial results for the three months ended March 31, 2022.

 

FIRST QUARTER 2022 HIGHLIGHTS

 

 

Capital Return

 

o

Safeguard repurchased 147,795 shares on the open market at an average price of $5.27 per share, totaling $0.8 million.

 

o

Safeguard has repurchased $0.4 million of additional shares subsequent to the quarter-end on the open market at an average price of approximately $4.71 per share.

 

 

Exits & Deployments

 

o

Safeguard funded $2.0 million and $1.4 million of convertible loans to Prognos Health and Clutch Holdings, respectively, as part of financings in which other existing investors also participated.

 

 

Safeguard Company Performance

 

o

The aggregate trailing twelve-month revenues ending December 31, 2021 for nine of Safeguard’s companies, which excludes Other Ownership Interests and MediaMath, was $141 million, an increase of 16.2% from the comparable prior period.

 

o

Safeguard’s 1.3 million shares of Bright Health common stock experienced unrealized declines in fair value of $2.0 million. Based on the closing price as of March 31, 2022, the fair value of Safeguard’s Bright Health common stock was $2.6 million.

 

o

In April, MediaMath consummated a comprehensive recapitalization transaction in which Safeguard did not provide additional capital. As part of the recapitalization, Safeguard’s previous preferred equity instruments were cancelled, and we received new equity instruments which could have value in certain upside scenarios.

 

 

Financial Results

 

o

Cash, cash equivalents and restricted cash totaled $19.4 million at March 31, 2022.

 

o

The carrying value of the Company’s ownership interests totaled $24.1 million at March 31, 2022, which includes the Bright Health common stock noted above. The total cost of Safeguard’s ownership interests was $154.4 million.

 

o

Net loss for the three months ended March 31, 2022 was $6.7 million, or $0.40 per share, compared with net income of $17.6 million, or $0.84 per share, for the same period in 2021. The prior year period’s net income reflected gains from the sale of Zipnosis and T-REX Group.

 

 

Operating Costs

 

o

Safeguard continued to reduce its operating costs. General and administrative expenses totaled $1.2 million for the quarter as compared to $2.5 million for the comparable period of 2021.

 

o

Safeguard also continued to lower its corporate expenses,which totaled $0.8 million for the first quarter of 2022, as compared to $1.2 million for the comparable period of 2021, a 29% year-on-year decline.

 

 

Outlook

 

o

Safeguard will continue to closely manage corporate expenses in 2022 with a target of $3.5 million to $4.0 million for the year, exclusive of strategic transaction related expenses, if any.    

 

o

Safeguard continues to explore all options to maximize value and expects to provide an update on its strategic process with Houlihan Lokey no later than its Q3 2022 earnings call.

 

“We remain confident in the opportunities for our companies to generate substantial value to our shareholders. While we continue to work with each of our management teams to drive operational performance and attractive exits in a timely manner, we are exploring additional strategic paths to maximize shareholder value with our advisor, Houlihan Lokey. Additionally, we are using our excess cash to repurchase shares through our current buyback program at what we believe are attractive levels. We also recently announced some changes to our Board of Directors. We would like to thank our Chairman of the Board, Dr. Robert Rosenthal, who is not standing for re-election at this year’s annual shareholders meeting, for his 15 years of dedicated service to Safeguard Scientifics. It has been a pleasure working closely with Bob over the past two years and we wish him much success in his future endeavors. We are also excited to welcome our two new director nominees, Ross DeMont and Beth Michelson, who we believe will be great additions to the Board,” said Eric C. Salzman, Chief Executive Officer.

 


1 Corporate expenses are general and administrative expenses excluding depreciation, severance, stock-based compensation and other non-recurring items.  See full reconciliation in the financial section of this statement.

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 1 of 6

 

 

 

 

safeguard01.jpg

 

OWNERSHIP INTERESTS AT MARCH 31, 2022

Companies

Category

Acquisition Year

 

Primary

Ownership%

   

Fully Diluted

Ownership%

**

   

Carrying

Value

(in millions)

   

Cost

(in millions)

 
                                     
 

Initial Revenue Stage: Up to $1 million

 

None

                                   
 

Revenue of $1 million to $5 million

 

None

                                   
 

Revenue of $5 million to $10 million

 

Lumesis, Inc.

Financial Services

2012

    43.2 %     43.3 %   $ 1.6     $ 5.6  

Moxe +

Healthcare

2016

    27.6 %     25.5 %     3.2       7.5  
 

Revenue of $10 million to $20 million

 

Clutch Holdings, Inc.

Digital Media

2013

    41.7 %     33.2 %     5.5       18.3  

InfoBionic, Inc.

Healthcare

2014

    25.2 %     22.1 %     -       22.0  

meQuilibrium

Healthcare

2015

    31.9 %     22.3 %     1.3       14.0  

Syapse, Inc.

Healthcare

2014

    11.0 %     8.9 %     4.2       25.0  

Trice Medical, Inc.

Healthcare

2014

    12.6 %     9.0 %     0.8       11.8  
 

Revenue of $20 million to $50 million

 

Aktana, Inc.

Healthcare

2016

    13.4 %     11.4 %     -       15.9  

Prognos Health, Inc.

Healthcare

2011

    28.5 %     25.1 %     4.1       14.6  
 

Revenue greater than $50 million

 

MediaMath, Inc. *

Digital Media

2009

    13.2 % *     10.1 % *     -       15.5  
 

Other Ownership Interests

 

Bright Health Group

Healthcare

2021

                    2.6       -  

All others

Various

                    0.8       4.2  
               

TOTAL:

    $ 24.1     $ 154.4  

 

 

 

+ Company progressed into higher revenue stage this quarter.

 

* MediaMath’s April recapitalization transaction substantially reduced Safeguard’s ownership interests to less than 1% on a fully diluted basis through new equity instruments that could have value in certain upside scenarios.

 

** Based on information provided by each respective company. Assumes the conversion or exercise of all currently outstanding securities including the issuance of all shares available under authorized employee equity programs. Does not reflect liquidation preferences, priority payments, proceeds from option and/or warrant exercises or other company-specific transaction-related obligations in a liquidation or exit transaction.

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 2 of 6

 

 

 

safeguard01.jpg

 

CONFERENCE CALL AND WEBCAST DETAILS

 

Please call 10-15 minutes prior to the call to register.

 

Date: May 5, 2022

 

Time: 5:00 p.m. ET

 

Webcast: https://www.webcast-eqs.com/safeguard05052022_en/en

 

Live Number: 888-428-7458

 

Speakers: Chief Executive Officer, Eric C. Salzman; and Senior Vice President and Chief Financial Officer, Mark A. Herndon

 

Format: Discussion of the full year and fourth quarter’s financial results followed by Q&A

 

The replay will be available at Safeguard.com’s investor relations site under “Past events”. For more information please contact IR@safeguard.com. 

 

About Safeguard Scientifics

Historically, Safeguard Scientifics has provided capital and relevant expertise to fuel the growth of technology-driven businesses. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. Safeguard is currently pursuing a focused strategy to value-maximize and monetize its ownership interests over a multi-year time frame to drive shareholder value. For more information, please visit www.safeguard.com.

 

Forward-Looking Statements

Except for the historical information and discussions contained herein, statements contained in this release may constitute forward-looking statements. Our forward-looking statements are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Safeguards ability to maximize the value of monetization opportunities of its ownership interests and drive total shareholder returns. Safeguards initiatives taken or contemplated to enhance and unlock value for all of its shareholders, Safeguards efforts to execute on and implement its strategy to streamline its organizational structure, reduce its operating costs, pursue monetization opportunities for ownership interests and maximize the return of value to its shareholders, Safeguards ability to create, unlock, enhance and maximize shareholder value, the effect of Safeguards management succession plan on driving increased organizational effectiveness and efficiencies, the ability of the management team to execute Safeguards strategy, the availability of, the timing of, and the proceeds that may ultimately be derived from the monetization of ownership interests, Safeguards projections regarding the reduction in its ongoing operating expenses, Safeguards projections regarding annualized operating expenses and expected severance expenses, monetization opportunities for ownership interests, and the amount of net proceeds from the monetization of ownership interests that will enable the return of value to Safeguard shareholders after satisfying working capital needs and the timing of such return of value. Such forward-looking statements are not guarantees of future operational or financial performance and are based on current expectations that involve a number of uncertainties, risks and assumptions that are difficult to predict. Therefore, actual outcomes and/or results may differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the monetization of our ownership interests for maximum value or at all and the return of value to our shareholders, our ability to successfully execute on our strategy to streamline our organizational structure and align our cost structure to increase shareholder value, whether our strategy will better position us to focus our resources on the highest-return opportunities and deliver enhanced shareholder value, the ongoing support of our existing ownership interests, the fact that our companies may vary from period to period, challenges to achieving liquidity from our ownership interests, fluctuations in the market prices of our publicly traded holdings, if any, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, risks, disruption, costs and uncertainty caused by or related to the actions of activist shareholders, including that if individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create value for our shareholders and perceived uncertainties as to our future direction as a result of potential changes to the composition of our Board may lead to the perception of a change in the direction of our business, instability or a lack of continuity that may adversely affect our business, and risks associated with our ownership interests, including the fact that most of our ownership interests have a limited operating history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which our companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to predict or control. As a result of these and other factors, the Companys past operational and financial performance should not be relied on as an indication of future performance. Further information on the above risk factors and other potential factors that could affect our future business, operating results and financial condition is included in our Annual Report on Form 10-K for the year ended December 31, 2021 and other periodic filings with the Securities and Exchange Commission, including risks under the heading Risk Factors. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.

 

###

 

SAFEGUARD CONTACT:

Mark Herndon

Chief Financial Officer

(610) 975-4913

mherndon@safeguard.com

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 3 of 6

 

 

 

 

safeguard01.jpg

 

Safeguard Scientifics, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

 

   

March 31, 2022

   

December 31, 2021

 

Assets

               

Cash, cash equivalents and restricted cash

  $ 19,432     $ 24,764  

Ownership interests

    2,552       4,549  

Other current assets

    914       965  

Total current assets

    22,898       30,278  

Ownership interests in and advances

    21,573       21,972  

Other assets

    1,727       1,778  

Total Assets

  $ 46,198     $ 54,028  
                 

Liabilities and Equity

               

Other current liabilities

  $ 1,010     $ 1,734  

Total current liabilities

    1,010       1,734  

Lease liability - non-current

    1,589       1,678  

Other long-term liabilities

    50       50  

Total equity

    43,549       50,566  

Total Liabilities and Equity

  $ 46,198     $ 54,028  

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 4 of 6

 

 

 

safeguard01.jpg

 

Safeguard Scientifics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 

   

Three Months Ended

 
   

March 31,

 
   

2022

   

2021

 

Operating expenses

 

$

1,234

   

$

2,463

 

Operating loss

   

(1,234

)

   

(2,463

)

Other income (loss), net

   

(1,997

)

   

706

 

Interest, net

   

101

     

53

 

Equity income (loss), net

   

(3,579

)

   

19,329

 

Net income (loss) before income taxes

   

(6,709

)

   

17,625

 

Income tax benefit (expense)

   

     

 

Net income (loss)

 

$

(6,709

)

 

$

17,625

 

Net income (loss) per share:

               

Basic

 

$

(0.40

)

 

$

0.84

 

Diluted

 

$

(0.40

)

 

$

0.84

 

Weighted average shares used in computing income (loss) per share:

               

Basic

   

16,587

     

20,902

 

Diluted

   

16,587

     

20,930

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 5 of 6

 

 

 

safeguard01.jpg

 

Safeguard Scientifics, Inc.

Financial Data

(in thousands)

 

Additional Financial Information

 

Non-GAAP Measures

 

In discussing financial results and guidance, the Company refers to the measure "corporate expenses" which is not in accordance with Generally Accepted Accounting Principles (GAAP). We use this non-GAAP financial measure internally to make operating and strategic decisions, including evaluating our overall performance and as a factor in determining compensation for certain employees. We have defined corporate expenses as general and administrative costs excluding stock based compensation, severance costs, and non-recurring items and other.  Non-recurring items and other includes accruals related to the Company's LTIP plan that will not be paid until reaching a specified threshold within that plan. We believe presenting this non-GAAP financial measure provides additional information to facilitate comparison of our historical operating costs and their trends, and provides additional transparency on how we evaluate our cost structure. We also believe presenting this measure allows investors to view our performance using the same measure that we use in evaluating our performance and trends.

 

Corporate expenses reconciliation:

 

   

Three Months Ended

 
   

March 31,

 
   

2022

   

2021

 

Corporate expenses

  $ 845     $ 1,197  

Stock based compensation

    314       245  

Severance costs

          774  

Non-recurring items and other

    75       247  

General and administrative expenses

  $ 1,234     $ 2,463  

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved. 6 of 6

 

 
EX-101.SCH 3 sfe-20220505.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 sfe-20220505_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 sfe-20220505_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 sfe-20220505_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 safeguard01.jpg begin 644 safeguard01.jpg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htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information
May 05, 2022
Document Information [Line Items]  
Entity, Registrant Name Safeguard Scientifics, Inc.
Document, Type 8-K
Document, Period End Date May 05, 2022
Entity, Incorporation, State or Country Code PA
Entity, File Number 1-5620
Entity, Tax Identification Number 23-1609753
Entity, Address, Address Line One 150 N. Radnor Chester Rd., STE F-200
Entity, Address, City or Town Radnor
Entity, Address, State or Province PA
Entity, Address, Postal Zip Code 19087
City Area Code 610
Local Phone Number 293-0600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol SFE
Security Exchange Name NYSE
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000086115
XML 9 sfe20220504_8k_htm.xml IDEA: XBRL DOCUMENT 0000086115 2022-05-05 2022-05-05 false 0000086115 8-K 2022-05-05 Safeguard Scientifics, Inc. PA 1-5620 23-1609753 150 N. Radnor Chester Rd., STE F-200 Radnor PA 19087 610 293-0600 false false false false Common Stock SFE NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.sfe.com/20220505/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports sfe20220504_8k.htm ex_370903.htm sfe-20220505.xsd sfe-20220505_def.xml sfe-20220505_lab.xml sfe-20220505_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sfe20220504_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "sfe-20220505_def.xml" ] }, "inline": { "local": [ "sfe20220504_8k.htm" ] }, "labelLink": { "local": [ "sfe-20220505_lab.xml" ] }, "presentationLink": { "local": [ "sfe-20220505_pre.xml" ] }, "schema": { "local": [ "sfe-20220505.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sfe", "nsuri": "http://www.sfe.com/20220505", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sfe20220504_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.sfe.com/20220505/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sfe20220504_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220505/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001437749-22-011133-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-011133-xbrl.zip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

'S-)KM@=Z81C&IB7=3*AG@ MBU=(N+=.ST(W0@NO MW1N.<61]-G1*6^$W3SN0Y$[KJDT-N/D(>A 5DBYS,8\B3IF$ M@CC5O+='P@%1(X9-D>"*PP1:$'S18,C(J:NPV3DN5]XVM] GX4H[; +Q',G/ MGQD%C\2D(NP6>A&AFYFW5]M*)TS>^C$'B6[-@Q'' #3RZ&P&P[(@2V=NM#-L M&2>IN7=)9Z2Z3W#(;"7:>98,3=KG"CQW%-"!#B^-Q_XE@G%7>K'8@26 M?+*8=[G\\_:)X):8US#\=Y$Y)0PDE@:24 X2:\AFZ9.T@P]8S=N6!#(F7]+ TXW& JD5E%Y[PQ[ M',-6^7'.?08=^DQHXCM6]:!DOY/]IH]-V7 YPM2HD>% J6\Z!?7Q8+6_' M!_@5^O?='KXHG_/:7&'X'D+8+L@_(&J7'C=Q?3B8.]-=FW;*XNZ]J_%:]C;# M\9A+B=Q$JTB,2KY3+)MBBS].V9"OW>F2UGCBAS/0C?89N0H+&;2+C=4'^#5! M7%''GN_![HX'NU7[#<))F7\\X4'S#%!5-4F5P72H1[@A^2124!( M.EYAGW1[+7)NE>Q-(=9;HDT3_GHM>N%=H"EC2)*Y]GYC_Y'ESA0B[9NOQ0VD M'ASW?W4F^=?[F M8V9AT>M&@+;P"?5):\K<2/%;1JX'D)0P^3L"GS=/09!P@B*^FP'.=ZN@+JN^ MO_QT5'(.ZQ*(Y[/)* P8"73XO$] P/P(PRQ"!:-@3CRV71%_:6/0BYQ"YX55 M.7"R'6B_83UNY"\AB/ -SC>9@!^7+?M@G8]^R[LQL/BK4!$ZF?B@VR"VN-RU MV_!9BO([M\I+U8T[\WA@9N-&^>:S.%L:@*2R9UD#, #G HQG=D[$"1^G!M6 M/L M@V#(/-+%:(1\H5+%6UP[LXGP!.E)88&XUOVJ-S!!7$0X 4C%@'=3TF=^ M>(=$P$8D#3FR/I.!/OM'.) 'SUUY0!P5$LG'D:]HP,)(^C,BJ>)R,-,]XPYA M'XA/XR*+;DCLU.CC8(0&LWG;(/0!.?;#*C3';%Z2_ EO2(;'G1KQ>3*?M ,8 M(C+%F]-"J6!FO5=[:;(]I:K>#T._3V%AX%*F2?/U3\$5T!(K%U$05Q(E"L#Q M8:527[5=) 8'I$EX,DGL4W(:6R70# !^5Y MIPC6#<&PP5J"X25(*R#UUU-K"0L6P0#?)Y53H9932E KM86_H%7%+AC(UT6N M&\%0MO ,G3Y8@FHK(#Y$1[F.;-#'7<[8L:P;\8E)2R5\1%,@)>99!W#T0(7^PR@RX-F_[T*^;VJD";Z ML^8SQ3@R?J4!:D2"7?86+^- 4@S[>7N?X/_WZF1C5;Y:.'C-Z6E6#?Y83Z2' M)^?-X2EW1%R?2KDYAX]):.I;FM:&N(^@9JE2<)Z1FG.N HJU\]DEB@NJ,]ON M;-P/_?Q#-9.7%NV*4ZB\3=&>']+2DLWF#@T,^=V(PYNEM?^Q9<5G4*AG-D]S M63)&?MV$8B"QR-UW7.\>5^2)PX*94^IK$PFY*T11(#Q=%;I?[\5<^;\6')M, MJ""WU(^R:GR[;4-?+9]B:VJ,*41SYZW''4)Z!E8\LP7]XVK?:FZ$-OO^F<"Y M9LY3%'-X&.?_KU!\-?JYR%^VWD%Z&[7W%)9VX&'.Q_ 2I*L+;]#\%;P?TT>1 M5JIB7!(:$$@8<80A&8KP3HTP=9Q@I8Q*XK$!#\S99E/PL:L9MQ&6EQ#*)/_+ M3\[!85T7?>; @ 8X,\&3T5@$-?EGJ6^5MKS9L!@4<]%EO\2PA5>@08QG[EX*3D(=5TADDQ# 6/BTC9^/H'K6H.Y9XDLTKC\&2*_ MXX :N1O ;HH:B05 MKD 6G%U[E_(%[C8^?*_Q121')[X?KJPB_9/DU;M!Y75 $I<R2/+@4/>93L>APNZ">GO@?1IHS (U%P3KCY M+< U4G"'DBGMO,#O@:O#_HF.^JS(TM?Q8/&E(>TGS?:OD(I\B_35.V*\ZB45 M[HB4'3/C CD%@S99[/VNCI^>#P;%2E'P[![81,' <5*,2T>\SR&S.2XX6C M#%LA!N"+@_/FXR.+STF\YJ@TA:4WTKOQ2]K+$<2,.J;I,T@2(%3RYEP?<)]Y M,<\UCR "F822:>5:1"!'6X;^^TA[.C9C8R @&E M\82^OZ"\/D^5LO#K!9ILN6T+SJG7NB3'!=M98\^W]TW//K6ET]''E7%#UWBC MV K)W75!.RQ8P_4@5]8E#97$T"Z@/9!*CKWF!M?^JH9PXA?OL,R M0RQK)T7LTBB\B]L.BAN&(]M;_J=\:!_;9?Q*W(+? M6.RR8 A!755C1K*AUXV._#IQY(8D%-T,01G)# M(2!I8VD!%H:'\L^HHN9:8MZ$:SAGB%+:^H.6!+]HN;>;JOQB)1FLG&Q=DBF] MYG)*5FWD-28?#Y\^[[8OKDY[OW9:W5TZ:/]"I\KGKBGV*,G/19F*\[>(BSA* MW#:MRBA5>Q&D+BZ-L+RL=U?,QY00#60W$K@!#9"\04P +R#K&6!Z@P/IL"$& MP*0X"J"/'@[!Y[Z+/69*(%\#@84#Y,5?*;3.A MTALY\5#?[F-7NWK9\>7EXKO+PM/F4*Z^X"3>N;T#W%ZYQOW.\%=F9O'+C#62 M^BSC4R\HOR'G\VE6>SH=GED'?JP7WKH"5I1%M@? MV57_<4,X/'A8,Q0AZ9\L07F7D#^8A"S^E"OWLG=+OXMOW]1BL=GFW_.;R/@! M3,G\=['Z06*5&;GM2,7TRVFW9RWKE)G'TAY]W&Q#T337*&\\@@5_B:F"_[V4 MQO\!4$L! A0#% @ +(*E5!(%-&"6*@ .QH" T ( ! M &5X7S,W,#DP,RYH=&U02P$"% ,4 " L@J540)0E)'8# F#@ M$ @ '!*@ 3 /@\ ,MK 2 M " 4<^ !S9F4R,#(R,#4P-%\X:RYH=&U02P4& 8 !@!_ 0 M4T # end